Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
Today, Thursday March 9, The Hill is hosting an important conversation titled: “Prescription for Change: Improving Competition to Lower Drug Prices,” featuring: David Schweikert (R-AZ), Member, Ways & Means Committee Tina Smith (D-MN), Member, Senate HELP Committee Lauren Aronson, Executive
PhRMA was one of AAN’s biggest donors the previous year, giving it $6.1 million, federal regulatory findings show
Though drug makers continue to raise prices out of proportion to increases in value, PBMs are doing their job by keeping drug costs down
Even including discounts, however, the company’s net profit margin for 2017 was 34 percent, its highest since at least 2000, when it was half that high.
This practice, the HHS inspector general said, could harm patients, the government and taxpayers because people might take pricey drugs instead of cheaper ones.
PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year
Mark Merritt said “we always support, as an industry, patients paying lower price at the counter…it’s an outlier practice.”
©2024 PCMA. All Rights Reserved.
